CTLA4 and melanoma: In conclusion, we report the efficacy of a combined intraperitoneal anti-PD-L1 and anti-CTLA-4 immunotherapy in a F16-B10 murine melanoma model by DWI MRI and ex vivo fluorescence immunohistochemistry.